Research Triangle Park, N.C. | January 27, 2026 — Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on inherited retinal diseases, has launched a first-in-human clinical trial evaluating OPGx-MERTK, an investigational AAV-based gene therapy for MERTK-related retinitis pigmentosa, a rare genetic disorder that causes progressive vision loss and eventual blindness. The trial, funded through Abu Dhabi’s Healthcare Research and Innovation Fund, will be conducted at Cleveland Clinic Abu Dhabi, marking a major milestone for precision medicine and rare disease research in the region
Science Significance
From a scientific standpoint, this trial represents a meaningful advance in ocular gene therapy, targeting the underlying genetic cause of MERTK-related retinitis pigmentosa rather than addressing symptoms alone. Mutations in the MERTK gene impair retinal cells’ ability to recycle photoreceptor outer segments, leading to progressive degeneration of the retina. OPGx-MERTK is designed to deliver a functional copy of the MERTK gene directly to retinal cells, potentially restoring critical cellular processes required for photoreceptor survival. With an estimated 60,000 patients worldwide affected and no approved treatments currently available, the study highlights the growing maturity of AAV-mediated gene delivery as a viable therapeutic strategy for inherited retinal diseases.
Regulatory Significance
Regulatorily, the launch of this trial underscores increasing global alignment around advanced therapy medicinal products (ATMPs) and gene therapy clinical governance. The study will be conducted under Good Clinical Practice (GCP) standards, with oversight from health authorities in Abu Dhabi and collaboration with international clinical and regulatory stakeholders. The program reflects how regional innovation ecosystems can support highly regulated therapies while maintaining rigorous safety and ethical standards. For Opus Genetics, this trial represents a critical step toward future regulatory submissions by generating first-in-human safety and efficacy data for OPGx-MERTK.
Business Significance
Advertisement
Regulatorily, the launch of this trial underscores increasing global alignment around advanced therapy medicinal products (ATMPs) and gene therapy clinical governance. The study will be conducted under Good Clinical Practice (GCP) standards, with oversight from health authorities in Abu Dhabi and collaboration with international clinical and regulatory stakeholders. The program reflects how regional innovation ecosystems can support highly regulated therapies while maintaining rigorous safety and ethical standards. For Opus Genetics, this trial represents a critical step toward future regulatory submissions by generating first-in-human safety and efficacy data for OPGx-MERTK
Patients’ Significance
For patients and families affected by MERTK-related retinitis pigmentosa, the trial offers the first tangible opportunity for a disease-modifying therapy. The condition often leads to irreversible blindness, significantly impacting independence and quality of life. A one-time gene therapy capable of slowing or halting disease progression could transform the long-term outlook for affected individuals. The initiation of clinical development in Abu Dhabi also improves geographic access to cutting-edge therapies, particularly in regions with a higher prevalence of inherited retinal diseases. This trial therefore represents both clinical hope and global inclusivity in rare disease research.
Policy Significance
At a policy level, the study reflects how government-backed research funding and international collaboration can accelerate innovation in rare diseases. Abu Dhabi’s support for this program demonstrates a strategic commitment to becoming a global hub for precision medicine and life sciences research. Such initiatives align with broader health policy goals aimed at supporting orphan drug development, fostering public–private partnerships, and ensuring early patient access to transformative therapies. The Opus trial serves as a model for how policy frameworks can effectively enable high-risk, high-impact biomedical research.
With the launch of its MERTK gene therapy clinical trial, Opus Genetics advances the frontier of precision ophthalmology and reinforces the promise of gene therapy for inherited retinal diseases. By combining robust scientific rationale, global clinical collaboration, and supportive innovation policy, the program has the potential to reshape treatment paradigms for patients facing inevitable vision loss. As clinical development progresses, the trial may not only redefine outcomes for MERTK-related retinitis pigmentosa but also contribute valuable insights to the broader field of regulated gene therapy development.
Source: Opus Genetics press release
